AVICANNA INC News

Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter

Best Quarterly Results in Company's History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox in Colombia

GlobeNewswireMay 14 07:35 ET

CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment

There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB), but treatments to help alleviate and control the symptoms do exist. The growing body of research suggests canna

BenzingaMay 13 13:56 ET

Avicanna Announces Results of Study in Patients With Epidermolysis Bullosa

The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13,

GlobeNewswireMay 13 07:30 ET

Avicanna Announces Closing of Non-brokered Private Placement

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization

GlobeNewswireApr 18 17:00 ET

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence ("RWE") study using RHO Phyto branded cannabigerol ("CBG") transdermal gel on patients with musculoskeletal pain and inflammation.

GlobeNewswireApr 10 08:37 ET

Earnings Call Summary | AVICANNA INC(AVCNF.US) Q4 2023 Earnings Conference

The following is a summary of the Avicanna Inc. (AVCNF) Q4 2023 Earnings Call Transcript:Financial Performance:Avicanna reported total revenue of $16.8 million for 2023, a 314% growth from the previou

moomoo AIApr 2 09:58 ET · Conference Call

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), the cannabinoids-focused biopharmaceutical company reported its year-end 2023 results and audited financial statements on Tuesday.The Canadian compan

BenzingaApr 2 09:18 ET

Avicanna Inc. Celebrates Soaring 2023 Profits

TipRanksApr 2 08:18 ET

Avicanna Reports Full Year 2023 Audited Financial Results

$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the

GlobeNewswireApr 2 07:30 ET

Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Avicanna

GlobeNewswireMar 27 08:02 ET

Avicanna To Hold Full Year 2023 Earnings Conference Call

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of

GlobeNewswireMar 26 07:30 ET

This Company Is Bringing Medical Marijuana Telehealth To Over Half The U.S.

MMJ.com which helps patients access medical marijuana through a telehealth platform, announced on Friday that it is expanding its services to 26 states.The move is expected to facilitate online consul

BenzingaMar 1 11:29 ET

Stocks in Play: Avicanna Inc.

Baystreet.caFeb 29 09:42 ET

Avicanna Hosts Symposium on Cannabinoid-based Medicine

TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of

GlobeNewswireFeb 29 07:30 ET

Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia's Weed Industry Goes Global

Clever Leaves Holdings Inc. (NASDAQ:CLVR) (OTC:CLVRW), a prominent global medical cannabis company announced a strategic partnership with the renowned Dutch seed bank, Paradise Seeds to develop and re

BenzingaFeb 14 11:21 ET

Avicanna Obtains Its First Indication-Specific Drug Registration With Trunerox

TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of

GlobeNewswireFeb 13 07:30 ET

CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal

Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) announced on Monday that it had reached an exclusive supply agreement for its two proprietary topical products with a multinational pharmaceutical com

BenzingaFeb 5 09:41 ET

Avicanna Signs Supply and Licensing Agreement With Pharmaceutical Company

Seeking AlphaFeb 5 08:06 ET

Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of

GlobeNewswireJan 30 07:30 ET

CBD-Focused Avicanna Announces Funding Boost For Research And Development

Cannabinoid-based biopharmaceutical company Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) announced on Monday that it has closed a non-brokered private placement offering of 2,537,508 ‎‎units of t

BenzingaDec 5, 2023 10:53 ET